The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1737
ISSUE1737
September 15, 2025
Acoltremon (Tryptyr) for Dry Eye Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Acoltremon (Tryptyr) for Dry Eye Disease
September 15, 2025 (Issue: 1737)
The FDA has approved acoltremon 0.003% ophthalmic
solution (Tryptyr – Alcon) for treatment of dry eye
disease. Acoltremon is the first transient receptor
potential melastatin 8 (TRPM8) thermoreceptor
agonist to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.